Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.
Alphabet Inc.’s Google has deepened its commitment to artificial intelligence (AI) by investing an additional $1 billion in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback